Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19684706 | 0.89 | ADORA1 (0.42) | ESR2PTGDR2NR1H2ADORA1GPR119 | |
| SCHEMBL19684705 | 0.89 | MKNK1 (0.41) | ESR2PTGDR2NR1H2ADORA1GPR119 | |
| SCHEMBL19684989 | 0.86 | DPP4 (0.39) | ESR2PTGDR2NR1H2ADORA1GPR119 | |
| SCHEMBL19684988 | 0.86 | PDE4D (0.45) | ESR2PTGDR2NR1H2ADORA1GPR119 | |
| SCHEMBL19667501 | 0.83 | PTGDR2 (0.46) | ESR2PTGDR2P2RX3 | |
| SCHEMBL19684982 | 0.82 | PTGDR2 (0.36) | ESR2PTGDR2NR1H2ADORA1GPR119 | |
| SCHEMBL19679345 | 0.82 | ADORA1 (0.45) | ESR2PTGDR2NR1H2ADORA1DPP4 | |
| SCHEMBL17462473 | 0.80 | ESR2 (0.49) | ESR2NR1H2ADORA1DPP4KDM4E | |
| SCHEMBL19667365 | 0.78 | ESR2 (0.47) | ESR2PTGDR2NR1H2ADORA1P2RX3 | |
| SCHEMBL30207961 | 0.78 | ESR2 (0.47) | ESR2PTGDR2NR1H2ADORA1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | ESR2 2951/4885PTGDR2 4262/4885NR1H2 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.